story of the week
Efficacy of CTC Count–Driven vs Clinician-Driven First-Line Therapy Choice in HR+, ERBB2− Metastatic Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
JAMA Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Efficacy of Circulating Tumor Cell Count-Driven vs Clinician-Driven First-Line Therapy Choice in Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: The STIC CTC Randomized Clinical Trial
JAMA Oncol 2020 Nov 05;[EPub Ahead of Print], FC Bidard, W Jacot, N Kiavue, S Dureau, A Kadi, E Brain, T Bachelot, H Bourgeois, A Gonçalves, S Ladoire, H Naman, F Dalenc, J Gligorov, M Espié, G Emile, JM Ferrero, D Loirat, S Frank, L Cabel, V Diéras, L Cayrefourcq, C Simondi, F Berger, C Alix-Panabières, JY PiergaFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.